Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04770545 · ClinicalTrials.gov registry record · Phase 3
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
A Phase 3 study, sponsored by Apellis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 792
- Enrollment target
NCT04770545 is a Phase 3 study that has completed, run by Apellis Pharmaceuticals. The registered enrollment target is 792 participants.
The verdict
NCT04770545, a Phase 3 study, has completed, sponsored by Apellis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 792 participants
- Enrollment target
Study Summary
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).
Interventions
- DRUG PEGCETACOPLAN (APL-2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 792 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2025-09-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04770545
The ClinicalTrials.gov registry entry for NCT04770545 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 792 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PEGCETACOPLAN (APL-2) is the first listed.
NCT04770545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04770545 about?
NCT04770545 is a clinical study titled "An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD". This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment ...
What is the current status of trial NCT04770545?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 792 participants. The study started on 2021-03-04. Estimated completion is 2025-09-05.
What interventions are being tested in trial NCT04770545?
The interventions under investigation include: PEGCETACOPLAN (APL-2) (DRUG).
Who is sponsoring clinical trial NCT04770545?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.